These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8550792)

  • 1. Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis.
    Johansson AG; Lindh E; Blum WF; Kollerup G; Sørensen OH; Ljunghall S
    J Clin Endocrinol Metab; 1996 Jan; 81(1):44-8. PubMed ID: 8550792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study.
    Brixen K; Kassem M; Nielsen HK; Loft AG; Flyvbjerg A; Mosekilde L
    J Bone Miner Res; 1995 Dec; 10(12):1865-74. PubMed ID: 8619366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of short-term insulin-like growth factor-I (IGF-I) or growth hormone (GH) treatment on bone metabolism and on production of 1,25-dihydroxycholecalciferol in GH-deficient adults.
    Bianda T; Glatz Y; Bouillon R; Froesch ER; Schmid C
    J Clin Endocrinol Metab; 1998 Jan; 83(1):81-7. PubMed ID: 9435420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women.
    Ghiron LJ; Thompson JL; Holloway L; Hintz RL; Butterfield GE; Hoffman AR; Marcus R
    J Bone Miner Res; 1995 Dec; 10(12):1844-52. PubMed ID: 8619364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency.
    Magnusson P; Degerblad M; Sääf M; Larsson L; Thorén M
    J Bone Miner Res; 1997 Feb; 12(2):210-20. PubMed ID: 9041052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normal osteoclastic and osteoblastic responses to exogenous growth hormone in patients with postmenopausal spinal osteoporosis.
    Kassem M; Brixen K; Blum WF; Mosekilde L; Eriksen EF
    J Bone Miner Res; 1994 Sep; 9(9):1365-70. PubMed ID: 7817819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human insulin-like growth factor I, recombinant human growth hormone, and sex steroids: effects on markers of bone turnover in humans.
    Mauras N; Doi SQ; Shapiro JR
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2222-6. PubMed ID: 8964855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
    Laursen T; Jørgensen JO; Jakobsen G; Hansen BL; Christiansen JS
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study.
    Hansen TB; Brixen K; Vahl N; Jørgensen JO; Christiansen JS; Mosekilde L; Hagen C
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3352-9. PubMed ID: 8784096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
    Joseph F; Ahmad AM; Ul-Haq M; Durham BH; Whittingham P; Fraser WD; Vora JP
    J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
    Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum insulin/like growth factor I, bone mineral density and biochemical markers of bone metabolism in children with idiopathic osteoporosis.
    Chlebna-Sokol D; Rusinska A
    Endocr Regul; 2001 Dec; 35(4):201-8. PubMed ID: 11858767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone secretion and sensitivity in men with idiopathic osteoporosis.
    Gillberg P; Johansson AG; Blum WF; Groth T; Ljunghall S
    Calcif Tissue Int; 2001 Feb; 68(2):67-73. PubMed ID: 11310349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I.
    Kurland ES; Chan FK; Rosen CJ; Bilezikian JP
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2576-9. PubMed ID: 9661647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum free insulin-like growth factor I (IGF-I), total IGF-I, and IGF-binding protein-3 concentrations in normal children and children with growth hormone deficiency.
    Kawai N; Kanzaki S; Takano-Watou S; Tada C; Yamanaka Y; Miyata T; Oka M; Seino Y
    J Clin Endocrinol Metab; 1999 Jan; 84(1):82-9. PubMed ID: 9920066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-I in men with idiopathic osteoporosis.
    Kurland ES; Rosen CJ; Cosman F; McMahon D; Chan F; Shane E; Lindsay R; Dempster D; Bilezikian JP
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2799-805. PubMed ID: 9284699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers.
    de Boer H; Blok GJ; Popp-Snijders C; Stuurman L; Baxter RC; van der Veen E
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1371-7. PubMed ID: 8636336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone status during long-term hexarelin therapy.
    Rahim A; O'Neill PA; Shalet SM
    J Clin Endocrinol Metab; 1998 May; 83(5):1644-9. PubMed ID: 9589671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GH and IGF-I as therapeutic agents for osteoporosis.
    Agnusdei D; Gentilella R
    J Endocrinol Invest; 2005; 28(8 Suppl):32-6. PubMed ID: 16323827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.